Creative Medical Technology Holdings, (NASDAQ:CELZ) declares IRB Approval to proceed with its Clinical Trial for the treatment of Type 1 Diabetes

According to cnn: In early 2020, as they tried to fight covid-19 across two rural counties in North Carolina, the staff of Granville Vance Public Health was stymied, relying on outdated technology to track a fast-moving pandemic.

Lisa Macon Harrison, the agency’s health director, said her nurses’ contact-tracing process required manually entering case information into five data systems. One was decades old and complicated. Another was made of Excel spreadsheets. None worked well together or with systems at other levels of government.

“We were using a lot of resources putting an inordinate amount of data into multiple systems that weren’t necessarily scaled to talk to each other or to the federal level,” Harrison said.

That poor interface between systems meant staff often lacked insight into what was happening elsewhere in the state and beyond. The staffers relied on “watching the news shows every morning to get the latest and greatest updates from other levels of government,” Harrison said.

The pandemic, which has killed more than 1 million Americans, highlighted ineffective data infrastructure across the U.S. health system, in a country that’s home to some of the world’s most influential technology companies: Coronavirus case reports sent by fax machine. Clunky tech for monitoring vaccine distribution — and major gaps in tracking who got jabbed. State-level data out of sync with federal figures. Supply chain breakdowns that left health care providers without needed protective equipment.

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ended higher 103.16% and complete the day at $1.0400. The total number of shares changed hands during the day was 137,280,906 shares. After opening at $1.3700, the stock hit as high as $1.4200. However, it traded between $0.3300 and $5.1450 over the last twelve months. Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, recently declared that it has received Institutional Review Board (IRB) approval to proceed with its Clinical Trial for the treatment of Type 1 Diabetes with its CELZ-201 cell therapy. The U.S. Food and Drug Administration (FDA) had previously cleared the Company’s Investigational New Drug (IND) application within 30 days from submission.

The Company believes that CELZ-201 leverages a unique approach to harnessing the power of Perinatal Tissue Derived Cells® (PRDC) to multi-potentialities, including self-renewal ability, low antigenicity, reduced toxicity, and large-scale clinical expansion. The primary objective of the study is to evaluate CELZ-201 as a treatment for patients with newly diagnosed Type 1 Diabetes.

The company sponsored trial will be conducted at the University of Miami Health System in conjunction with the Diabetes Research Institute.

“The purpose of IRB review and approval is to assure that appropriate steps are taken to protect the rights and welfare of patients participating as subjects in the research and is an important milestone in proceeding with a clinical trial. We are pleased with achieving IRB approval expeditiously and look forward to moving forward with our Phase 1/2 clinical trial,” Said Timothy Warbington, CEO of Creative Medical Technology Holdings, Inc.

“I am excited to proceed with the CELZ-201 perinatal cell product in this study, as I believe that if successful it could result in a promising treatment for many patients with Type 1 Diabetes,” said Dr. Camillo Ricordi, Principal Investigator.

Michael Bond

Michael Bond

Leave a Reply

Your email address will not be published. Required fields are marked *